Icon Plc (NASDAQ:ICLR) – Equities research analysts at First Analysis issued their Q3 2018 earnings estimates for shares of Icon in a report released on Monday. First Analysis analyst T. Van. Fleet anticipates that the medical research company will post earnings per share of $1.50 for the quarter.

Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Jefferies Group reiterated a “buy” rating and issued a $122.00 price target on shares of Icon in a report on Tuesday, September 12th. ValuEngine downgraded Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Barclays increased their price target on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Friday, October 27th. Finally, Bank of America initiated coverage on Icon in a report on Monday, September 11th. They issued a “buy” rating and a $128.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Icon presently has a consensus rating of “Buy” and a consensus price target of $121.00.

Icon (NASDAQ:ICLR) traded down $0.73 during mid-day trading on Tuesday, hitting $111.18. The stock had a trading volume of 447,800 shares, compared to its average volume of 360,759. The firm has a market cap of $6,060.15, a P/E ratio of 21.48, a price-to-earnings-growth ratio of 1.73 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a 1-year low of $73.76 and a 1-year high of $124.48.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon had a return on equity of 28.42% and a net margin of 16.37%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.19 EPS.

Large investors have recently bought and sold shares of the business. IHT Wealth Management LLC boosted its position in Icon by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after buying an additional 24 shares during the last quarter. Acrospire Investment Management LLC boosted its position in Icon by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC boosted its position in Icon by 20.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after buying an additional 217 shares during the last quarter. SG Americas Securities LLC purchased a new position in Icon in the 3rd quarter valued at about $148,000. Finally, Commonwealth Equity Services Inc purchased a new position in Icon in the 3rd quarter valued at about $208,000. 89.95% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/icon-plc-iclr-to-post-q3-2018-earnings-of-1-50-per-share-first-analysis-forecasts/1759847.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.